ShigETEC live, attenuated, oral vaccine

BIOLOGICAL2 trials

Sponsors

Eveliqure Biotechnologies GmbH

Conditions

Diarrheal Disease, InfectiousGastrointestinal DiseaseHealthy VolunteersReactive Arthritis

Phase 1

Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults

CompletedNCT05409196

Eveliqure Biotechnologies GmbHDiarrheal Disease, Infectious, Gastrointestinal Disease, Reactive Arthritis

Start: 2020-09-16End: 2021-06-21Updated: 2022-06-08

ShigETEC Vaccine Study in Bangladesh

CompletedNCT05987488

Eveliqure Biotechnologies GmbHHealthy Volunteers

Start: 2023-11-26End: 2025-12-01Updated: 2026-01-23